Obsessive-Compulsive Disorder in Dermatology

Obsessive-compulsive disorder (OCD) is a very common disorder affecting 2% to 3% of the general population. Up to 25% of patients presenting to physicians with skin disease suffer from OCD. Only 20% of all patients with OCD are receiving treatment. Unfortunately, those few receiving treatment remained undiagnosed for many years. Standard treatment includes behavioral therapy and psychotropic drugs (ie, selective serotonin re-uptake inhibitors and clomipramine). The highest dosages of these medications must be used for at least 3 months to see proper effectiveness and maintained for lengthy periods of time. Not only are there abnormalities in the serotonin pathway of patients with OCD but also the glutamate pathway is abnormal, leading to possible new treatment strategies. Semin Cutan Med Surg 32:83-87 © 2013 Frontline Medical CommunicationsObsessive-compulsive disorder (OCD) is a very common disorder affecting 2% to 3% of the general population. Up to 25% of patients presenting to physicians with skin disease suffer from OCD. Only 20% of all patients with OCD are receiving treatment. Unfortunately, those few receiving treatment remained undiagnosed for many years. Standard treatment includes behavioral therapy and psychotropic drugs (ie, selective serotonin re-uptake inhibitors and clomipramine). The highest dosages of these medications must be used for at least 3 months to see proper effectiveness and maintained for lengthy periods of time. Not only are there abnormalities in the serotonin pathway of patients with OCD but also the glutamate pathway is abnormal, leading to possible new treatment strategies. Semin Cutan Med Surg 32:83-87 © 2013 Frontline Medical Communications

Purchase this article:

PURCHASE FOR $25

For unlimited access to all issues and articles:

If you do not subscribe to Seminars in Cutaneous Medicine and Surgery, you may purchase instant access for your personal use. Terms and conditions will apply (see Copyright & Terms of Use). If you need assistance, contact Susan Hite ([email protected]).